Study on the Effect of Combined Estrogen and Progestogen Therapy on Endometrial Repair After Induced Abortion

Postoperative care after induced abortion should prioritize the issue of endometrial repair. In 2021, the Family Planning Branch of the Chinese Medical Association published the "Expert Consensus on Promoting Endometrial Repair After Induced Abortion" [10], emphasizing the importance of endometrial repair for high-risk populations following induced abortion. Currently, clinically, methods to promote endometrial repair include estrogen-progestin medications, compound short-acting oral contraceptives, traditional Chinese medicine, and bioelectric stimulation. However, controversies still exist regarding endometrial repair, and selecting an effective and safe treatment plan remains crucial. This study aims to prospectively evaluate the efficacy and safety of estradiol/estradiol/dydrogesterone in endometrial repair after induced abortion through clinical research, providing a basis for endometrial repair and ovarian function recovery post-abortion.

Inclusion criteria

• Age between 18 years old (inclusive) and 40 years old (inclusive)
• Body Mass Index (BMI) ranging from 18.5Kg/㎡ to 23.9Kg/㎡
• Experienced at least 2 abortions or had a missed abortion
• Confirmed gestational age of no more than 10 weeks, and the ultrasonic examination within three days prior to the surgery shows a gestational sac (average of three diameters) of at least 1.0cm, with an embryo length of no more than 3.0cm
• Normal preoperative examination results as per the "Clinical Diagnosis and Treatment Guidelines and Technical Operation Standards: Family Planning Volume (2017 Revision)"
• Capable of regular follow-ups and willing to sign the informed consent form.

Exclusion criteria

• Individuals with contraindications to estrogen and progesterone therapy
• History of uterine adhesions confirmed by hysteroscopy, or a history of uterine cavity surgery or uterine malformation correction
• Subjects who require placement of an intrauterine device or administration of oral contraceptives or subcutaneous implants after the procedure
• Individuals with mental status or cognitive function abnormalities who are unable to cooperate with the treatment process
• Subjects who, in the opinion of the investigator, have potential risks or any other factors that may interfere with the study.